Checking Kidney and Heart Markers in Children With New Type 1 Diabetes
Compares blood markers of organ injury in children with new diabetes, with and without ketoacidosis.
Plain-language title generated from the registry record
Registry title: Biomarkers of Acute Organ Injury in Pediatric Newly Diagnosed Type 1 Diabetes
Key facts
- Where
- Thessaloniki, GreeceSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 2 and 16 years old?
Source: NCT07483879, who can take part
Where in Greece
- Hippokration General Hospital of ThessalonikiThessaloniki, GreeceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Aristotle University Of Thessaloniki
- Trial code
- NCT07483879
- Record updated
- 19 March 2026
- Original description
Diabetic ketoacidosis (DKA) is a severe metabolic complication in children with newly diagnosed type 1 diabetes mellitus (T1DM) and may be associated with early injury of vital organs such as the kidneys and the heart. Early detection of organ dysfunction is important for identifying children at increased risk for complications.Read full original descriptionShow less
Evaluation of Biomarkers and Clinical Parameters of Acute Organ Injury in Children With Newly Diagnosed Type 1 Diabetes: The Effect of Diabetic Ketoacidosis
Diabetic ketoacidosis (DKA) is a severe metabolic complication in children with newly diagnosed type 1 diabetes mellitus (T1DM) and may be associated with early injury of vital organs such as the kidneys and the heart. Early detection of organ dysfunction is important for identifying children at increased risk for complications.
This observational cross-sectional study aims to evaluate biomarkers of acute organ injury and associated clinical and echocardiographic parameters in children with newly diagnosed T1DM presenting with DKA, compared with children with newly diagnosed T1DM without DKA and healthy controls. Biomarkers including KIM-1, NGAL, high-sensitivity troponin, NT-proBNP, interleukin-6, and C-reactive protein will be measured during hospital admission and within the first 24-48 hours of hospitalization.
Inclusion: Children aged 2-16 years; Newly diagnosed type 1 diabetes mellitus; Hospital admission for initial evaluation and treatment; Presence or absence of diabetic ketoacidosis at diagnosis; Written informed consent from parents or legal guardians; For control group:; Age-matched healthy children without diabetes.
Exclusion: Previous diagnosis of diabetes mellitus; Known chronic kidney disease; Known cardiovascular disease; Acute infection or inflammatory condition unrelated to diabetes; Use of medications that may affect renal or cardiac biomarkers.